AllianceBernstein
DSGN icon

AllianceBernstein’s Design Therapeutics DSGN Stock Holding History

AllianceBernstein’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$433K Hold
46,120
– – ﹤0.01% 2709
2025
Q4 		$433K Hold
46,120
– – ﹤0.01% 2728
2025
Q3 		$347K Buy
46,120
+1,090
+2% +$5.46K ﹤0.01% 2871
2025
Q2 		$152K Buy
45,030
+2,940
+7% +$11K ﹤0.01% 3112
2025
Q1 		$162K Hold
42,090
– – ﹤0.01% 2975
2024
Q4 		$260K Hold
42,090
– – ﹤0.01% 2946
2024
Q3 		$226K Hold
42,090
– – ﹤0.01% 3004
2024
Q2 		$141K Buy
42,090
+4,590
+12% +$17.9K ﹤0.01% 3080
2024
Q1 		$151K Hold
37,500
– – ﹤0.01% 2973
2023
Q4 		$99.4K Sell
37,500
-3,900
-9% -$8.93K ﹤0.01% 3068
2023
Q3 		$97.7K Hold
41,400
– – ﹤0.01% 3073
2023
Q2 		$261K Buy
41,400
+10,200
+33% +$62.4K ﹤0.01% 2915
2023
Q1 		$180K Buy
31,200
+3,600
+13% +$26.9K ﹤0.01% 2934
2022
Q4 		$283K Buy
27,600
+6,400
+30% +$86.7K ﹤0.01% 2895
2022
Q3 		$354K Buy
21,200
+7,200
+51% +$143K ﹤0.01% 2794
2022
Q2 		$196K Buy
+14,000
New +$189K ﹤0.01% 3032

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein's DSGN Position: Q1 2026 in Review

AllianceBernstein held its Design Therapeutics (DSGN) position steady in Q1 2026 at 46,120 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #2709.

AllianceBernstein first reported a position in DSGN in Q2 2022 and has held it in 16 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • AllianceBernstein held 46,120 shares of Design Therapeutics worth $433K as of Q1 2026.
  • AllianceBernstein left its Design Therapeutics share count unchanged in Q1 2026.
  • Design Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2709 holding.
  • AllianceBernstein first reported a position in Design Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.